Lymphoepithelioma-Like Bladder Carcinoma: A Diagnostic and Therapeutic Challenge. Contribution Using a New Case and Review of the Literature

Survival Analysis of Lymphoepithelioma-Like Carcinoma of the Urinary Bladder and the Effect of Surgical Treatment Modalities on Prognosis

“…Finally, chemotherapy was not identified as a prognosticator in this study. However, insufficient information on chemotherapy regimen and responses might overshadow the findings of this study, considering that the existing evidence suggesting the use of platinum-based chemotherapy perioperatively might have the potential to improve outcomes (9,10,14).…”

“…Despite the lack of such categorization in the SEER database, we rationally assumed that the SEER cohort was comparable to the literature data set because prognostic factors and OS were similar between the two groups. According to a previous review (14), a mass of LELCB of pure and predominant subtypes were successfully treated with TURBT or partial cystectomy, followed by adjuvant therapy, ending up with no evidence of recurrence or progression (33). Furthermore, Yang et al ( 15) found a higher rate of no evidence of disease and a significantly lower rate due to death of disease in patients receiving TURBT combined with radiotherapy or chemotherapy after pooling 140 cases from published literature (15).…”

“…A total of 60 patients diagnosed with LELCB with a median age of 69.5 (interquartile range: 61-75 years) were identified in the SEER database from 1999 to December 2015. LR was performed, and 95 cases from 28 published articles in English from 1993 to 2021 were extracted to verify the performance of prognostic classification derived from the SEER cohort (Supplementary Figure 1) (2,9,10,(12)(13)(14)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32). The baseline characteristics, including age, gender, radiation therapy, tumor extent, and surgery approaches, were statistically similar in both data sets, except for the administration of chemotherapy (Table 1).…”

“…Previous studies revealed a favorable outcome of LELCB compared with that of conventional urothelial carcinoma and most other histological variants (4). However, whether it is appropriate to treat muscle-invasive LELCB with bladder-sparing surgery (BSS), including transurethral resection of bladder tumor (TURBT) or partial cystectomy, followed by adjuvant treatment, remains controversial (12)(13)(14)(15). In the light of previous experience, effective bladder-sparing therapy (BST) for muscle-invasive bladder cancer requires a judicious selection of patients based on prognostic profiles and risk prediction models.…”

Lymphoepithelioma-Like Carcinoma of the Bladder: A Case Report of a Rare and Particular Variant of Urothelial Carcinoma

“…The existing therapeutic procedures are TURBT, partial cystectomy, and radical cystectomy for primary treatments while adjuvant treatments include systemic chemotherapy, radiotherapy, combined chemotherapy and radiotherapy, and intravesical chemotherapy and as reported in the review of Rodríguez-Cabello et al, with a favorable outcome, disease-free survival rate was higher than 80% in the pure and predominant forms confirming their good prognosis [ 16 ].…”